Barack Obama’s recent riffs about President Trump (“He’s got the White House looking like Saddam Hussein opened a Cheesecake Factory!”) and Trump’s rambling response (“I passed three cognitive tests. I’m the only President that agreed to take them. And they’re hard, you know? Obama—Obama couldn’t have passed it.”) underscored the split-screen reality of the midterm elections, Susan B. Glasser writes. “Two Presidents, two Americas. For ten endless years, our politics has been all about the vast gap that separates these two men, and the near-impossible task of trying to understand how a country that elected Obama twice could, so soon after, do the same for Trump. Watching them both on Wednesday night, toggling between screens and alternate universes as they shot barbs at each other, was a reminder of how very long we’ve been stuck in this loop. “What’s different this time is a sense—and, until there are votes counted and races called, it’s just a sense—that real-world events have intervened to make this less of an intractably divided country and more of a place where at least some shared truths are still possible.” Glasser reflects on Obama, Trump, and the midterms that may see the country bridging its divides: newyorkermag.visitlink.me/62…

Thank you to Dr. Lidia Schapira (@l_schapira) of Stanford University for our afternoon keynote, Reimagining Cancer Survivorship: From Discovery to Delivery, Locally and Globally, and to Dr. @CarmenCalfa for moderating. Learn more about our Sylvester Cancer Survivorship Symposium: spr.ly/6017BHUYVx.

1/7 🫁 What happens when a patient with stage III lung cancer starts neoadjuvant chemoimmunotherapy but can no longer undergo surgery? MDT-BRIDGE, a new phase II study in Nature Medicine, addresses this important clinical dilemma. @SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @Latinamd @LuisPaz_Ares @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @LungCancerEu @alissajcooper @BZhangMD @NaglaAKarimMD @Annechiangmd @IASLC @NCCN @ASCO #ESMO26 @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @colazagasti @openmedicineHQ @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @OncodailyLung @ClinicalLung #LCSM @LungPolicy @dan_morgxen @LAGurwitch

🎉Congratulations to the newly appointed #FASCO @ASCO members! @christinemphmd @Joshua_Reuss @NazliDizman @ryangentzler

🏴‍☠️ Ahoy, mateys! Even at the doctor’s office, we’re sailing through Halloween! A little pirate spirit, a lot of team spiri! ☠️🎃 Who says you can’t have fun at a hospital? Happy Halloween from our crew! 🩺🏴‍☠️ #HalloweenAtWork #PirateCrew #DoctorLife #Teamwork @SylvesterCancer

"Make It So” “The first duty of every Starfleet officer is to the truth, whether it's scientific truth, or historical truth, or personal truth!" #RIPPatrickStewart 🖤

ASCO Election The ASCO Nominating Committee has selected 11 distinguished members as candidates for open leadership positions within the Society. ASCO encourages all eligible members to cast their ballots to choose new Society leaders. Eligible members are those who have been awarded and hold the degree of Doctor of Medicine, Doctor of Osteopathy, Doctor of Philosophy, Doctor of Pharmacy, Doctor of Medical Science, Doctor of Nursing Science, Doctor of Nursing Practice, or equivalent doctoral-level degree as determined by the Society and the Association, and who are in good standing as of October 13, 2026. Eligible members will earn a FASCO point for voting in the ASCO Election.   The voting period closes on Wednesday, December 2, 2026, at 3:00 PM Eastern Standard Time, USA. All ballots (online or paper) must be received by this time. @iaslc #WCLC26 @oncoalert @oncodaily @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @latinamd @colazagasti @openmedicineHQ @asco @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @lungoncdoc @OncodailyLung @ClinicalLung #LCSM

You have my vote 🗳️@RManochakian @MayoClinic for @ASCO Nominating Committee 👇

The link between obesity and early-onset cancer. A nationwide study of 6.3 million people, age 20-39, with no prior cancer, by BMI and waist circumference, with 11 year follow-up, in South Korea acpjournals.org/doi/full/10.… @AnnalsofIM

Why I voted early 🗳️ because this midterm election matters. Top policy priorities for doctors in the 2026 midterm elections 🩺🇺🇸 1️⃣Medicare reimbursement — Fair, predictable physician payment updates that reflect practice costs. 2️⃣Prior authorization reform — Reduce delays, denials, and administrative burdens. 3️⃣Medicaid access — Protect continuity of coverage and access to providers. 4️⃣Research funding — Sustain NIH, cancer research, and clinical trial funding 5️⃣Affordable healthcare — Improve insurance affordability and provider network access. 6️⃣Prescription drug access — Address medication costs and access to innovative treatment 7️⃣Public health and prevention — Support vaccination, screening, and evidence-based prevention. 8️⃣Patient safety — Promote evidence-based scope-of-practice policies and accountable team-based care. #ASCOAdvocacy #FixPriorAuthorization #NIHFunding #AMA @dadecountymed

This is the post of the day for me. Video of T-cell engagers engaging in the lab . thanks for sharing. #Thanksscience #immunotherapy

We are all done with #ESMO26! 10+ studies that were on our radar and the updated data around them. Out in the community settings, it’s tough to keep up with all that is happening here in the world of cancer (and this was just ONE conference). Really appreciate you all sharing the data and importantly your take around this: @OncoAlert @weoncologists @DrChoueiri @StephenVLiu @SuyogCancer @dr_yakupergun @drsarahsam @PTarantinoMD @GIMedOnc @BijoyTelivala @RenoHemonc @nlindenberg @jryckman3 @ErikaHamilton9 @myESMO @LorenzaRimassa 🙏🏽🙏🏽

PANKU-Lung01 at #ESMO26: promising phase III results for EGFR×HER3 bispecific ADC iza-bren after EGFR TKI. PFS: 11.1 vs 5.7 mo (HR 0.40). ORR: 60.2% vs 34.5%. OS immature. China-only trial; global validation and optimal sequencing remain important. #LungCancer

#ESMO26 The brilliant Dr. @marinagarassino with biomarker analysis from the phase III KEYNOTE 671 study of perioperative pembrolizumab for resectable NSCLC showing association of T-cell inflamed gene expression profile and TMB with efficacy. Benefit across subgroups; inflamed profile associated with better prognosis. #ESMOAmbassadors

The day is coming…